Abstract

A method for disrupting the formation of CCR9:DRD5 heteromer assembly in a subject involving administering to the subject a pharmaceutical composition having at least on disrupter agent that inhibits or blocks the interaction between CCR9 and DRD5. Also, peptides and peptide analogs for use as the disrupter agent and pharmaceutical compositions containing the peptides and peptide analogs.